Efficacy and Safety of Voclosporin in Patients with Proteinuria > 2 G/g (ACR Convergence 2023) - Sep 24, 2023 - Abstract #2326; Pres time: Nov 14, 2023; 09:00 AM - 11:00 AM; Location: Poster Hall; in person; "In a pooled analysis of the Phase 2 AURA-LV and Phase 3 AURORA 1 studies, the addition of voclosporin to mycophenolate mofetil (MMF) and low-dose glucocorticoids resulted in earlier and greater reductions in proteinuria, regardless of baseline demographics or disease characteristics. Consistent with results from the overall pooled study population, patients with UPCR =2 g/g treated with voclosporin achieved significantly higher renal response rates than patients treated with MMF and low-dose glucocorticoids alone while renal function in both arms remained comparable. This is clinically relevant given the lack of safe and effective therapies for patients with high proteinuria. E."
Clinical • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Disease
|
|
Emily Littlejohn1; Salem Almaani2; Vanessa Birardi3; Ernie Yap4; Christopher Collins5
|